Apogee Therapeutics Plunges 18.63% Amid Insider Selling

On April 7, 2025, Apogee Therapeutics experienced a significant drop of 18.63% in pre-market trading, reflecting a notable decline in investor sentiment.

Recent insider trading activities have been a focal point for Apogee Therapeutics. CEO Michael Thomas Henderson sold 15,000 shares of the company's stock on January 8th, which may have contributed to the market's negative perception. Additionally, the company's chief medical officer, Carl Dambkowski, sold $139,801 worth of stock on April 2nd, further adding to the concerns about the company's future prospects.

These insider sales, totaling nearly $1 million, have coincided with a drop in Apogee Therapeutics' market value to $1.9 billion, indicating a potential loss of confidence among key stakeholders. The cumulative effect of these transactions has likely influenced the recent market downturn, as investors may be interpreting these moves as a sign of internal pessimism.